Sanofi and Biovac Announce Partnership to Manufacture Inactivated Polio Vaccines in Africa; Biovac Becomes First African Producer of IPV; Aims to Serve Over 40 African Countries and Supports Africa CDC's Goal for 60% Local Vaccine Production by 2040
Portfolio Pulse from Benzinga Newsdesk
Sanofi and Biovac have announced a partnership to manufacture inactivated polio vaccines (IPV) in Africa. Biovac will become the first African producer of IPV, aiming to serve over 40 African countries and support the Africa CDC's goal for 60% local vaccine production by 2040.
June 20, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sanofi has partnered with Biovac to manufacture inactivated polio vaccines in Africa. This partnership will make Biovac the first African producer of IPV, aiming to serve over 40 African countries and support the Africa CDC's goal for 60% local vaccine production by 2040.
The partnership with Biovac positions Sanofi as a key player in the African vaccine market, potentially increasing its market share and revenue. The initiative aligns with global health goals and could enhance Sanofi's reputation and influence in the region.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100